PWM
REGN icon

Perigon Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Perigon Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.93M Sell
7,680
-156
-2% -$119K 0.11% 177
2025
Q4 		$6.05M Buy
7,836
+1,135
+17% +$771K 0.11% 171
2025
Q3 		$3.77M Buy
6,701
+985
+17% +$557K 0.08% 243
2025
Q2 		$3M Sell
5,716
-1,432
-20% -$799K 0.07% 263
2025
Q1 		$4.53M Sell
7,148
-17
-0.2% -$11.7K 0.12% 176
2024
Q4 		$4.97M Sell
7,165
-1,396
-16% -$1.17M 0.12% 161
2024
Q3 		$9M Buy
8,561
+242
+3% +$269K 0.24% 91
2024
Q2 		$8.74M Buy
8,319
+239
+3% +$232K 0.25% 80
2024
Q1 		$7.78M Buy
8,080
+1,968
+32% +$1.87M 0.24% 96
2023
Q4 		$5.37M Buy
6,112
+161
+3% +$133K 0.18% 123
2023
Q3 		$4.9M Buy
5,951
+560
+10% +$440K 0.2% 112
2023
Q2 		$3.87M Buy
5,391
+320
+6% +$247K 0.15% 139
2023
Q1 		$4.17M Buy
5,071
+240
+5% +$181K 0.24% 97
2022
Q4 		$3.49M Buy
4,831
+386
+9% +$285K 0.22% 109
2022
Q3 		$3.06M Buy
4,445
+1,205
+37% +$758K 0.26% 81
2022
Q2 		$1.92M Buy
3,240
+149
+5% +$96.9K 0.16% 131
2022
Q1 		$2.16M Sell
3,091
-430
-12% -$272K 0.15% 126
2021
Q4 		$2.22M Buy
3,521
+13
+0.4% +$7.99K 0.16% 122
2021
Q3 		$2.12M Buy
3,508
+37
+1% +$23K 0.18% 109
2021
Q2 		$1.94M Buy
3,471
+15
+0.4% +$7.6K 0.17% 115
2021
Q1 		$1.64M Buy
3,456
+2,122
+159% +$1.03M 0.17% 120
2020
Q4 		$644K Sell
1,334
-86
-6% -$46.4K 0.07% 208
2020
Q3 		$795K Buy
1,420
+85
+6% +$51.5K 0.11% 151
2020
Q2 		$833K Sell
1,335
-1
-0.1% -$568 0.13% 127
2020
Q1 		$685K Buy
1,336
+581
+77% +$240K 0.13% 133
2019
Q4 		$281K Sell
755
-2
-0.3% -$673 0.06% 207
2019
Q3 		$230K Hold
757
– – 0.05% 209
2019
Q2 		$237K Buy
757
+50
+7% +$16.6K 0.06% 207
2019
Q1 		$247K Buy
707
+47
+7% +$19.4K 0.06% 187
2018
Q4 		$276K Sell
660
-52
-7% -$19K 0.07% 170
2018
Q3 		$288K Sell
712
-158
-18% -$60.1K 0.07% 179
2018
Q2 		$300K Buy
870
+808
+1,303% +$253K 0.09% 181
2018
Q1 		$21K Buy
+62
New +$21.6K 0.01% 432
2017
Q4 		– Sell
-464
Closed -$207K – 664
2017
Q3 		$207K Sell
464
-949
-67% -$452K 0.07% 197
2017
Q2 		$694K Buy
1,413
+54
+4% +$23.6K 0.15% 147
2017
Q1 		$527K Buy
1,359
+70
+5% +$25.9K 0.11% 171
2016
Q4 		$488K Buy
1,289
+248
+24% +$94.3K 0.11% 177
2016
Q3 		$419K Sell
1,041
-14
-1% -$5.62K 0.11% 157
2016
Q2 		$368K Buy
+1,055
New +$406K 0.1% 159

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Perigon Wealth Management's REGN Position: Q1 2026 in Review

Perigon Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2% in Q1 2026, selling an estimated $119K and leaving 7,680 shares worth $5.93M. The position accounts for 0.11% of the portfolio, ranked #177.

Perigon Wealth Management first reported a position in REGN in Q2 2016 and has held it in 39 quarters since. The position peaked at $9M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Perigon Wealth Management held 7,680 shares of Regeneron Pharmaceuticals worth $5.93M as of Q1 2026.
  • Perigon Wealth Management sold 156 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $119K.
  • Regeneron Pharmaceuticals made up 0.11% of Perigon Wealth Management's portfolio in Q1 2026, its #177 holding.
  • Perigon Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
  • Perigon Wealth Management's Regeneron Pharmaceuticals position peaked at $9M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Perigon Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.